# Geno.Me

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geno-me

- Industry: Healthcare
- Headquarters: Madison, US
- Website: www.yourgeno.me
- Total disclosed funding: $0.4M
- Latest round: Seed (Nov 15, 2021)
- Investors on record: 1

## About

Geno.Me specializes in advanced genomic analysis technologies, providing insights into genetic data for researchers and clinicians. Their offerings enhance diagnostic accuracy and patient outcomes through personalized healthcare solutions.Geno.Me is focused on genomic analysis, delivering high-throughput sequencing and bioinformatics tools. Founded by MIO Britt Gottschalk, the company is headquartered in Madison, US. In November 2021, it raised USD 400,000 in Seed funding from Gateway Capital Partners, marking its first deal.Geno.Me provides advanced genomic analysis technologies that offer in-depth insights into genetic data. Their main product lines include high-throughput sequencing platforms and bioinformatics tools, enabling the identification of genetic disorders and personalized treatment plans. The company caters to a diverse clientele, including academic institutions and healthcare providers, primarily across North America, Europe, and parts of Asia.Geno.Me generates revenue through direct sales and subscription models, with clients engaging in annual contracts for genomic analysis platforms. Pricing is tiered based on usage and service levels, and the company offers training and support to enhance customer satisfaction and loyalty.Geno.Me plans to utilize the recent Seed funding of USD 400,000 raised in November 2021 to support the development of new genomic products and expand into additional markets, including targeted regions in Asia. These initiatives aim to enhance their service offerings and reach a broader client base by the end of 2023.

## Funding rounds

- Seed, Nov 15, 2021, $0.4M — Gateway Capital Partners

## Investors

- Gateway Capital Partners (https://capitalatlas.ai/funds/gateway-capital-partners) — Seed